{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T14:15:08Z","timestamp":1740147308883,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:00:00Z","timestamp":1689811200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001593","name":"Irish Cancer Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001593","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ir J Med Sci"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s11845-023-03370-1","type":"journal-article","created":{"date-parts":[[2023,7,20]],"date-time":"2023-07-20T00:01:42Z","timestamp":1689811302000},"page":"65-71","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["P53 loss of heterozygosity (LOH) in formalin-fixed paraffin-embedded leiomyosarcoma (LMS): a novel report"],"prefix":"10.1007","volume":"193","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2842-1814","authenticated-orcid":false,"given":"John N.","family":"McMahon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eoin F.","family":"Gaffney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William J.","family":"Aliaga-Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John F.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amirhossein","family":"Jalali","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bernadette","family":"Curran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,7,20]]},"reference":[{"key":"3370_CR1","volume-title":"Soft Tissue Tumors","author":"FM Enzinger","year":"2019","unstructured":"Enzinger FM, Weiss SW (2019) Soft Tissue Tumors. Elsevier, USA"},{"key":"3370_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00346.Accessed01May2019","author":"MF Xue","year":"2019","unstructured":"Xue MF, Chen G, Dai JP et al (2019) Development and validation of a prognostic nomogram for extremity soft tissue leiomyosarcoma. Front Oncol. https:\/\/doi.org\/10.3389\/fonc.2019.00346.Accessed01May2019","journal-title":"Front Oncol"},{"key":"3370_CR3","doi-asserted-by":"publisher","first-page":"3501","DOI":"10.1158\/1078-0432.CCR-14-3141","volume":"21","author":"X Guo","year":"2015","unstructured":"Guo X, Jo VY, Mills AM et al (2015) Clinically relevant molecular subtypes in leiomyosarcoma. Clin Cancer Res 21:3501\u20133511. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-3141","journal-title":"Clin Cancer Res"},{"key":"3370_CR4","unstructured":"Bunz F, Vogelstein B (2018) Cancer Genetics. In: Jameson, Fauci, Kasper \u2018et al\u2019(eds) Harrison\u2019s Principles of Internal Medicine, 20th edn. McGraw-Hill Education, USA, pp 452\u201360"},{"key":"3370_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.3390\/ph14010057","volume":"14","author":"X Zhang","year":"2021","unstructured":"Zhang X, Sj\u00f6blom T (2021) Targeting loss of heterozygosity: a novel paradigm for cancer therapy. Pharmaceuticals (Basel) 14:57. https:\/\/doi.org\/10.3390\/ph14010057","journal-title":"Pharmaceuticals (Basel)"},{"key":"3370_CR6","unstructured":"Bunz F, Vogelstein B\n(2018) Cancer Genetics. In: Jameson, Fauci, Kasper et al. (eds) Harrison\u2019s\nPrinciples of Internal Medicine, 20th edn. McGraw-Hill Education,\nUSA, pp 455\u00a0"},{"key":"3370_CR7","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.1126\/science.1235122","volume":"339","author":"B Vogelstein","year":"2013","unstructured":"Vogelstein B, Papadopoulos N, Velculescu VE et al (2013) Cancer Genome Landscapes. Science 339:1546\u20131558. https:\/\/doi.org\/10.1126\/science.1235122","journal-title":"Science"},{"key":"3370_CR8","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41431-020-00774-w","volume":"29","author":"S Tapial","year":"2020","unstructured":"Tapial S, Garcia JL, Corchete L et al (2020) Copy neutral loss of heterozygosity (cnLOH) patterns in synchronous colorectal cancer. Eur J Hum Genet 29:709\u2013713. https:\/\/doi.org\/10.1038\/s41431-020-00774-w","journal-title":"Eur J Hum Genet"},{"key":"3370_CR9","doi-asserted-by":"publisher","unstructured":"Lee GT, Chung YJ (2022) Comparison of the copy-neutral loss of heterozygosity identified from whole-exome sequencing data using three different tools Genom Inform 20:e4.\u00a0https:\/\/doi.org\/10.5808\/gi.21066","DOI":"10.5808\/gi.21066"},{"key":"3370_CR10","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1007\/BF02973397","volume":"163","author":"EF Gaffney","year":"1994","unstructured":"Gaffney EF, Dervan PA, McCabe MM et al (1994) Soft tissue and visceral sarcomas in Irish patients. Ir J Med Sci 163:240\u2013245. https:\/\/doi.org\/10.1007\/BF02973397","journal-title":"Ir J Med Sci"},{"key":"3370_CR11","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.5858\/arpa.2013-0691-RA","volume":"138","author":"BP Bass","year":"2014","unstructured":"Bass BP, Engel KB, Greytak SR et al (2014) A review of preanalytical factors affecting molecular, protein, and morphological analysis of formalin-fixed, paraffin-embedded (FFPE) tissue: how well do you know your FFPE specimen? Arch Pathol Lab Med 138:1520\u20131530. https:\/\/doi.org\/10.5858\/arpa.2013-0691-RA","journal-title":"Arch Pathol Lab Med"},{"key":"3370_CR12","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1177\/39.6.1709656","volume":"39","author":"SR Shi","year":"1991","unstructured":"Shi SR, Key ME, Kaira KL (1991) Antigen retrieval in formalin-fixed, paraffin-embedded tissues: an enhancement method for immunohistochemical staining based on microwave oven heating of tissue sections. J Histochem Cytochem 39:741\u2013748. https:\/\/doi.org\/10.1177\/39.6.1709656","journal-title":"J Histochem Cytochem"},{"key":"3370_CR13","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1111\/j.1365-2559.1994.tb00532.x","volume":"24","author":"LX Pan","year":"1994","unstructured":"Pan LX, Diss TC, Peng HZ et al (1994) Clonality analysis of defined B-cell populations in archival tissue sections using microdissection and the polymerase chain reaction. Histopath 24:323\u2013327. https:\/\/doi.org\/10.1111\/j.1365-2559.1994.tb00532.x","journal-title":"Histopath"},{"key":"3370_CR14","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1016\/0006-291x(85)90390-0","volume":"130","author":"SE Goelz","year":"1985","unstructured":"Goelz SE, Hamilton SR, Vogelstein B (1985) Purification of DNA from formaldehyde fixed and paraffin embedded human tissue. Biochem Biophys Res Commun 130:118\u2013126. https:\/\/doi.org\/10.1016\/0006-291x(85)90390-0","journal-title":"Biochem Biophys Res Commun"},{"key":"3370_CR15","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1038\/bjc.1993.236","volume":"67","author":"L Cawkwell","year":"1993","unstructured":"Cawkwell L, Bell SM, Lewis FA et al (1993) Rapid detection of allele loss in colorectal tumours using microsatellites and fluorescent DNA technology. Br J Cancer 67:1262\u20131267. https:\/\/doi.org\/10.1038\/bjc.1993.236","journal-title":"Br J Cancer"},{"key":"3370_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/bjc.1994.404","volume":"70","author":"L Cawkwell","year":"1994","unstructured":"Cawkwell L, Lewis FA (1994) Quirke, P (1994) Frequency of allele loss of DCC, p53, RBI, WTI, NFI, NM23 and APC\/MCC in colorectal cancer assayed by fluorescent multiplex polymerase chain reaction. Br J Cancer 70:813\u2013818. https:\/\/doi.org\/10.1038\/bjc.1994.404","journal-title":"Br J Cancer"},{"key":"3370_CR17","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/0016-5085(95)90334-8","volume":"109","author":"L Cawkwell","year":"1995","unstructured":"Cawkwell L, Li D, Lewis FA et al (1995) Microsatellite instability in colorectal cancer: Improved assessment using fluorescent polymerase chain reaction. Gastroenterology 109:465\u2013471. https:\/\/doi.org\/10.1016\/0016-5085(95)90334-8","journal-title":"Gastroenterology"},{"key":"3370_CR18","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/gcc.2870050113","volume":"5","author":"MH Jones","year":"1991","unstructured":"Jones MH, Nakamura Y (1991) Detection of loss of heterozygosity at the human TP53 locus using a dinucleotide repeat polymorphism. Genes Chrom Cancer 5:89\u201390. https:\/\/doi.org\/10.1002\/gcc.2870050113","journal-title":"Genes Chrom Cancer"},{"key":"3370_CR19","unstructured":"Kellogg DE, Rybalkin I, Chen S et al (1994) TaqStart Antibody: hot start PCR facilitated by a neutralizing monoclonal antibody directed against Taq DNA polymerase. Biotechniques 16:1134\u20131137. (PMID: 8074881)"},{"key":"3370_CR20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/bjc.1993.333","volume":"68","author":"NA Gruis","year":"1993","unstructured":"Gruis NA, Abeln EC, Bardoel AF et al (1993) PCR-based microsatellite polymorphisms in the detection of loss of heterozygosity in fresh and archival tumour tissue. Br J Cancer 68:308\u2013313. https:\/\/doi.org\/10.1038\/bjc.1993.333","journal-title":"Br J Cancer"},{"key":"3370_CR21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.2307\/2335991","volume":"69","author":"DP Harrington","year":"1982","unstructured":"Harrington DP, Fleming TR (1982) A class of rank test procedures for censored survival data. Biometrika 69:553\u2013566. https:\/\/doi.org\/10.2307\/2335991","journal-title":"Biometrika"},{"key":"3370_CR22","doi-asserted-by":"crossref","unstructured":"Cox DR (1972) Regression models and life-tables. J Royal Statistical Soc Series B:Methodological 34: 187\u2013220. https:\/\/rss.onlinelibrary.wiley.com\/doi\/abs\/10.1111\/j.2517-6161.1972.tb00899.x","DOI":"10.1111\/j.2517-6161.1972.tb00899.x"},{"key":"3370_CR23","doi-asserted-by":"crossref","unstructured":"Venables WN, Ripley BD (2002) Modern Applied Statistics with S: Springer-Verlag, New York","DOI":"10.1007\/978-0-387-21706-2"},{"key":"3370_CR24","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","volume":"53","author":"EL Kaplan","year":"1958","unstructured":"Kaplan EL, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Statist Assoc 53:457\u2013481. https:\/\/doi.org\/10.1080\/01621459.1958.10501452","journal-title":"J Am Statist Assoc"},{"key":"3370_CR25","first-page":"5358","volume":"48","author":"FP Li","year":"1988","unstructured":"Li FP, Fraumeni JF, Mulvihill JJ et al (1988) A cancer family syndrome in twenty-four kindreds. Cancer Res 48:5358\u20135362 (PMID: 3409256)","journal-title":"Cancer Res"},{"key":"3370_CR26","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13058-019-1193-1","volume":"21","author":"F Batalini","year":"2019","unstructured":"Batalini F, Peacock EG, Stobie L et al (2019) Li-Fraumeni syndrome: not a straightforward diagnosis anymore \u2013 the interpretation of pathogenic variants of low allele frequency and differences between germline PVs, mosaicism, and clonal hematopoiesis. Breast Cancer Res 21:107. https:\/\/doi.org\/10.1186\/s13058-019-1193-1","journal-title":"Breast Cancer Res"},{"key":"3370_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.3748\/wjg.v11.i6.778","volume":"11","author":"SC Chang","year":"2005","unstructured":"Chang SC, Lin JK, Lin TC et al (2005) Loss of heterozygosity: an independent prognostic factor of colorectal cancer. World J Gastroenterol 11:778\u2013784. https:\/\/doi.org\/10.3748\/wjg.v11.i6.778","journal-title":"World J Gastroenterol"},{"key":"3370_CR28","doi-asserted-by":"publisher","first-page":"20198","DOI":"10.18632\/oncotarget.15560","volume":"8","author":"X Jia","year":"2017","unstructured":"Jia X, Shanmugam C, Paluri RK et al (2017) Prognostic value of loss of heterozygosity and sub-cellular localization of SMAD4 varies with tumor stage in colorectal cancer. Oncotarget 8:20198\u201320212. https:\/\/doi.org\/10.18632\/oncotarget.15560","journal-title":"Oncotarget"},{"key":"3370_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1016\/j.cancergencyto.2010.01.019","volume":"199","author":"EWS Soaresa","year":"2010","unstructured":"Soaresa EWS, Santos SCdeL, Bueno AG et al (2010) Concomitant loss of heterozygosity at the BRCA1 and FHIT genes as a prognostic factor in sporadic breast cancer. Cancer Genet Cytogenet 199:24\u201330. https:\/\/doi.org\/10.1016\/j.cancergencyto.2010.01.019","journal-title":"Cancer Genet Cytogenet"},{"key":"3370_CR30","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1002\/ijc.21178","volume":"117","author":"RC Tseng","year":"2005","unstructured":"Tseng RC, Chang JW, Hsien FJ et al (2005) Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int J Cancer 117:241\u2013247. https:\/\/doi.org\/10.1002\/ijc.21178","journal-title":"Int J Cancer"},{"key":"3370_CR31","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.1002\/cncr.20213","volume":"100","author":"EVS H\u00f8gdall","year":"2004","unstructured":"H\u00f8gdall EVS, Ryan A, Kjaer SK et al (2004) Loss of heterozygosity on the X chromosome is an independent prognostic factor in ovarian carcinoma. Cancer 100:2387\u20132395. https:\/\/doi.org\/10.1002\/cncr.20213","journal-title":"Cancer"},{"key":"3370_CR32","doi-asserted-by":"publisher","first-page":"7312","DOI":"10.1200\/JCO.2005.01.2799","volume":"23","author":"PE Grundy","year":"2005","unstructured":"Grundy PE, Breslow NE, Li S et al (2005) Loss of heterozygosity for chromosomes 1p and 16q is an adverse prognostic factor in favorable-histology Wilms tumor: a report from the National Wilms Tumor Study Group. J Clin Oncol 23:7312\u20137321. https:\/\/doi.org\/10.1200\/JCO.2005.01.2799","journal-title":"J Clin Oncol"},{"key":"3370_CR33","doi-asserted-by":"publisher","unstructured":"Pyke RM, Abbott C, Dea S et al (2021) Association of HLA loss of heterozygosity with allele-specific neoantigen expansion in response to immunotherapy. J Clin Oncol 39, (suppl 15) published online May 28.\u00a0https:\/\/doi.org\/10.1200\/JCO.2021.39.15_suppl.e18030","DOI":"10.1200\/JCO.2021.39.15_suppl.e18030"},{"issue":"suppl 1","key":"3370_CR34","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1186\/s12881-018-0722-6","volume":"19","author":"J Kim","year":"2018","unstructured":"Kim J, Kim JH, Kang HG et al (2018) Integrated molecular characterization of adult soft tissue sarcoma for therapeutic targets. BMC Med Genet 19(suppl 1):216. https:\/\/doi.org\/10.1186\/s12881-018-0722-6","journal-title":"BMC Med Genet"},{"key":"3370_CR35","doi-asserted-by":"publisher","first-page":"2517","DOI":"10.1038\/s41467-020-16399-y","volume":"11","author":"CA Nichols","year":"2020","unstructured":"Nichols CA, Gibson WJ, Brown MS et al (2020) Loss of heterozygosity of essential genes represents a widespread class of potential cancer vulnerabilities. Nat Commun 11:2517. https:\/\/doi.org\/10.1038\/s41467-020-16399-y","journal-title":"Nat Commun"},{"key":"3370_CR36","doi-asserted-by":"publisher","unstructured":"Alexandrova EM, Mirza SA, Xu S et al (2017) p53 loss-of-heterozygosity is a necessary prerequisite for mutant p53 stabilization and gain-of-function in vivo. Cell Death Dis 8:e2661. https:\/\/doi.org\/10.1038\/cddis.2017.80","DOI":"10.1038\/cddis.2017.80"},{"key":"3370_CR37","doi-asserted-by":"publisher","unstructured":"Hwang MS, Moga BJ, Douglass J et al (2021) Targeting loss of heterozygosity for cancer-specific immunotherapy. PNAS 118: e2022410118. https:\/\/doi.org\/10.1073\/pnas.2022410118","DOI":"10.1073\/pnas.2022410118"},{"key":"3370_CR38","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1373\/clinchem.2014.223040","volume":"61","author":"H Do","year":"2015","unstructured":"Do H, Dobrovic A (2015) Sequence artifacts in DNA from formalin-fixed tissues: causes and strategies for minimization. Clin Chem 61:64\u201371. https:\/\/doi.org\/10.1373\/clinchem.2014.223040","journal-title":"Clin Chem"},{"key":"3370_CR39","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1038\/gim.2017.241","volume":"20","author":"P Robbe","year":"2018","unstructured":"Robbe P, Popitsch N, Knight SJL et al (2018) Clinical whole-genome sequencing from routine formalin-fixed, paraffin-embedded specimens: pilot study for the 100,000 genomes project. Genet Med 20:1196\u20131205. https:\/\/doi.org\/10.1038\/gim.2017.241","journal-title":"Genet Med"},{"key":"3370_CR40","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1080\/10520295.2018.1446101","volume":"93","author":"EF Gaffney","year":"2018","unstructured":"Gaffney EF, Riegman PH, Grizzle WE et al (2018) Factors that drive the increasing use of FFPE tissue in basic and translational cancer research. Biotech Histochem 93:373\u2013386. https:\/\/doi.org\/10.1080\/10520295.2018.1446101","journal-title":"Biotech Histochem"},{"key":"3370_CR41","doi-asserted-by":"publisher","unstructured":"Einaga N, Yoshida A, Noda H et al (2017) Assessment of the quality of DNA from various formalin-fixed paraffin-embedded (FFPE) tissues and the use of this DNA for next-generation sequencing (NGS) with no artifactual mutation. PloS One 12:e0176280.\u00a0https:\/\/doi.org\/10.1371\/journal.pone.0176280","DOI":"10.1371\/journal.pone.0176280"},{"key":"3370_CR42","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s00109-020-01874-2","volume":"98","author":"Ramon y Cajal S, Ses\u00e9 M, Capdevila","year":"2020","unstructured":"Ramon y Cajal S, Ses\u00e9 M, Capdevila C et al (2020) Clinical implications of intratumor heterogeneity: challenges and opportunities. J Mol Med 98:161\u2013177. https:\/\/doi.org\/10.1007\/s00109-020-01874-2","journal-title":"J Mol Med"},{"key":"3370_CR43","doi-asserted-by":"publisher","first-page":"1900152","DOI":"10.1002\/adtp.201900152","volume":"3","author":"A Degl'Innocenti","year":"2020","unstructured":"Degl\u2019Innocenti A, di Leo N, Cioifani G (2020) Genetic hallmarks and heterogeneity of glioblastoma in the single-cell omics era. Adv Ther (Weinh) 3:1900152. https:\/\/doi.org\/10.1002\/adtp.201900152","journal-title":"Adv Ther (Weinh)"}],"container-title":["Irish Journal of Medical Science (1971 -)"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11845-023-03370-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11845-023-03370-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,24]],"date-time":"2024-01-24T05:50:33Z","timestamp":1706075433000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11845-023-03370-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,20]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["3370"],"URL":"https:\/\/doi.org\/10.1007\/s11845-023-03370-1","relation":{},"ISSN":["0021-1265","1863-4362"],"issn-type":[{"type":"print","value":"0021-1265"},{"type":"electronic","value":"1863-4362"}],"subject":[],"published":{"date-parts":[[2023,7,20]]},"assertion":[{"value":"25 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All 30 patients gave informed consent to provide clinical treatment and subsequent follow-up details to their clinical consultant and to have their data coordinated centrally in a dedicated database by a research assistant appointed by grants from The Irish Cancer Society. Ethical approval from Irish Research and Ethics Committees for research that posed only a negligible risk to patients, was not required. Selected specific additional patient data, including survival data, was obtained from medical records and then fully anonymised. There was no patient or public involvement in the design phase or logistics of this project or at any stage during the project itself. No additional data is available.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}